
Opinion|Videos|July 30, 2026
Interpreting the TOP Study and Comparing FLAURA2 and MARIPOSA Data
Author(s)Sandip Patel, MD, Chul Kim, MD
This segment interprets the TOP study findings and their practice implications.
Advertisement
Episodes in this series
This segment interprets the TOP study findings and their practice implications. The panel discusses how the trial's hazard ratios, for both progression-free and overall survival, compare with historical expectations in EGFR-mutated NSCLC and how the trial results impact their current practices. The discussion then situates the TOP study compared with TP53 subgroup findings from the FLAURA2 and MARIPOSA trials. The panel weighs these effect sizes against patient-specific factors and reinforces that identifying the EGFR mutation and TP53 status are useful steps in treatment planning.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

